Mirum Pharmaceuticals (FRA:08D) Treasury Stock: €0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:08D Mirum Pharmaceuticals Inc FRA:08D
52 GF Score
Price €78.04
GF Value €74.28
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Treasury Stock?

Mirum Pharmaceuticals FRA:08D -0.36% 52 Treasury Stock is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:08D with a GF Score™ of 52/100 and a GF Value™ of €74.28 (Fairly Valued). The stock has 5 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Mirum Pharmaceuticals's treasury stock for the quarter that ended in Jun. 2026 was €0.0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Mirum Pharmaceuticals Treasury Stock Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Treasury Stock Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Mirum Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:08D
52GF Score
Mirum Pharmaceuticals Inc FRA:08D
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of €0.0 Mil mean?
Mirum Pharmaceuticals (FRA:08D) has a Treasury Stock of €0.0 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Treasury Stock too high?
Mirum Pharmaceuticals' current Treasury Stock is €0.0 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Treasury Stock compare to DNTH and COGT?
Mirum Pharmaceuticals' Treasury Stock of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Treasury Stock is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (FRA:08D) is currently considered Fairly Valued. The stock's GF Value™ is €74.28, compared to a current price of €78.04 — trading 5.1% above its estimated fair value. The current Treasury Stock is €0.0 Mil. Mirum Pharmaceuticals' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Mirum Pharmaceuticals (FRA:08D), the current Treasury Stock is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (FRA:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €78.04 is trading 5.1% above its estimated GF Value™ of €74.28. GuruFocus considers Mirum Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:08D:

  • Treasury Stock: €0.0 Mil
  • GF Value™: €74.28 vs. price of €78.04 (5.1% above fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the FRA:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on therapies for rare and orphan liver diseases. Its lead product, Livmarli (maralixibat), is an orally administered ileal bile acid transporter inhibitor approved for cholestatic pruritus in patients with Alagille syndrome and for progressive familial intrahepatic cholestasis. The company also markets Cholbam (cholic acid) for bile acid synthesis disorders and Ctexli (chenodiol) for cerebrotendinous xanthomatosis. Mirum is developing volixibat for adult cholestatic liver conditions, including primary sclerosing cholangitis and primary biliary cholangitis. Its customers are primarily specialty pharmacies, hospitals, and healthcare providers in the United States and Europe, where it sells directly and through distributors. Revenue comes mainly from product sales of its approved medicines, supplemented by licensing and collaboration arrangements.
52GF Score

Get the complete analysis for FRA:08D

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.04
Price
€74.28
GF Value